Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment

Tingting Guo,1,2,* Yanying Zhao,2,3,* Shengnan Liang,2,3 Jie Wang,2 Hengwei Liu,2 Yufan Zhou,2 Heping Xu,3– 5 Zhongping Chen1– 3,6 1Aier Eye Hospital, Jinan University, Guangzhou, People’s Republic of China; 2Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Aier Aca...

Full description

Saved in:
Bibliographic Details
Main Authors: Guo T, Zhao Y, Liang S, Wang J, Liu H, Zhou Y, Xu H, Chen Z
Format: Article
Language:English
Published: Dove Medical Press 2025-01-01
Series:Journal of Inflammation Research
Subjects:
Online Access:https://www.dovepress.com/dynamic-complement-protein-changes-in-aqueous-humor-and-plasma-of-pati-peer-reviewed-fulltext-article-JIR
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832577691153334272
author Guo T
Zhao Y
Liang S
Wang J
Liu H
Zhou Y
Xu H
Chen Z
author_facet Guo T
Zhao Y
Liang S
Wang J
Liu H
Zhou Y
Xu H
Chen Z
author_sort Guo T
collection DOAJ
description Tingting Guo,1,2,&ast; Yanying Zhao,2,3,&ast; Shengnan Liang,2,3 Jie Wang,2 Hengwei Liu,2 Yufan Zhou,2 Heping Xu,3– 5 Zhongping Chen1– 3,6 1Aier Eye Hospital, Jinan University, Guangzhou, People’s Republic of China; 2Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China; 4Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, People’s Republic of China; 5The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK; 6School of Stomatology and Ophthalmology, Xianning Medical College, Xianning, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Zhongping Chen; Heping Xu, Email chenzhongping@csu.edu.cn; heping.xu@qub.ac.ukPurpose: To assess dynamic changes of complement protein in aqueous humor (AH) and plasma of retinal vein occlusion (RVO) patients during ranibizumab treatment, and to explore the differential expression of complement proteins in branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).Patients and Methods: This prospective, consecutive case series study collected AH and plasma samples from 27 RVO patients at baseline, 1 and 2 months after ranibizumab treatment, including 19 BRVO and 8 CRVO patients. The concentrations of 13 complement proteins and vascular endothelial growth factor A (VEGF-A) were measured using Luminex® × MAP® technology.Results: During ranibizumab treatment, a reduction in the levels of C1q (p < 0.001), C2 (p = 0.030), C4 (p = 0.001), C4b (p = 0.026), C3b/iC3b (p < 0.001), C5 (p = 0.007), C5a (p = 0.005), CFD (p = 0.022), CFH (p < 0.001), and CFI (p < 0.001) in AH was observed. No significant changes were observed in the plasma levels of all measured factors. At baseline, CRVO had higher levels of C4 (p = 0.003), C4b (p < 0.001), C3b/iC3b (p < 0.001), C5 (p = 0.020), C5a (p = 0.007), CFD (p = 0.002), CFH (p < 0.001), and CFI (p < 0.001) in AH compared to BRVO.Conclusion: Ranibizumab treatment reduced the intraocular but not circulating activation of classical and alternative complement pathways in RVO patients. Differences in intraocular complement proteins were observed between BRVO and CRVO patients, which may reflect different pathogenesis.Keywords: retinal vein occlusion, complement protein, aqueous humor, plasma
format Article
id doaj-art-a40aaf847842423492303073cf0d4bb4
institution Kabale University
issn 1178-7031
language English
publishDate 2025-01-01
publisher Dove Medical Press
record_format Article
series Journal of Inflammation Research
spelling doaj-art-a40aaf847842423492303073cf0d4bb42025-01-30T18:07:17ZengDove Medical PressJournal of Inflammation Research1178-70312025-01-01Volume 181435144599743Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab TreatmentGuo TZhao YLiang SWang JLiu HZhou YXu HChen ZTingting Guo,1,2,&ast; Yanying Zhao,2,3,&ast; Shengnan Liang,2,3 Jie Wang,2 Hengwei Liu,2 Yufan Zhou,2 Heping Xu,3– 5 Zhongping Chen1– 3,6 1Aier Eye Hospital, Jinan University, Guangzhou, People’s Republic of China; 2Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China; 4Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, People’s Republic of China; 5The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK; 6School of Stomatology and Ophthalmology, Xianning Medical College, Xianning, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Zhongping Chen; Heping Xu, Email chenzhongping@csu.edu.cn; heping.xu@qub.ac.ukPurpose: To assess dynamic changes of complement protein in aqueous humor (AH) and plasma of retinal vein occlusion (RVO) patients during ranibizumab treatment, and to explore the differential expression of complement proteins in branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).Patients and Methods: This prospective, consecutive case series study collected AH and plasma samples from 27 RVO patients at baseline, 1 and 2 months after ranibizumab treatment, including 19 BRVO and 8 CRVO patients. The concentrations of 13 complement proteins and vascular endothelial growth factor A (VEGF-A) were measured using Luminex® × MAP® technology.Results: During ranibizumab treatment, a reduction in the levels of C1q (p < 0.001), C2 (p = 0.030), C4 (p = 0.001), C4b (p = 0.026), C3b/iC3b (p < 0.001), C5 (p = 0.007), C5a (p = 0.005), CFD (p = 0.022), CFH (p < 0.001), and CFI (p < 0.001) in AH was observed. No significant changes were observed in the plasma levels of all measured factors. At baseline, CRVO had higher levels of C4 (p = 0.003), C4b (p < 0.001), C3b/iC3b (p < 0.001), C5 (p = 0.020), C5a (p = 0.007), CFD (p = 0.002), CFH (p < 0.001), and CFI (p < 0.001) in AH compared to BRVO.Conclusion: Ranibizumab treatment reduced the intraocular but not circulating activation of classical and alternative complement pathways in RVO patients. Differences in intraocular complement proteins were observed between BRVO and CRVO patients, which may reflect different pathogenesis.Keywords: retinal vein occlusion, complement protein, aqueous humor, plasmahttps://www.dovepress.com/dynamic-complement-protein-changes-in-aqueous-humor-and-plasma-of-pati-peer-reviewed-fulltext-article-JIRretinal vein occlusioncomplement proteinaqueous humorplasma
spellingShingle Guo T
Zhao Y
Liang S
Wang J
Liu H
Zhou Y
Xu H
Chen Z
Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment
Journal of Inflammation Research
retinal vein occlusion
complement protein
aqueous humor
plasma
title Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment
title_full Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment
title_fullStr Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment
title_full_unstemmed Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment
title_short Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment
title_sort dynamic complement protein changes in aqueous humor and plasma of patients with retinal vein occlusion during ranibizumab treatment
topic retinal vein occlusion
complement protein
aqueous humor
plasma
url https://www.dovepress.com/dynamic-complement-protein-changes-in-aqueous-humor-and-plasma-of-pati-peer-reviewed-fulltext-article-JIR
work_keys_str_mv AT guot dynamiccomplementproteinchangesinaqueoushumorandplasmaofpatientswithretinalveinocclusionduringranibizumabtreatment
AT zhaoy dynamiccomplementproteinchangesinaqueoushumorandplasmaofpatientswithretinalveinocclusionduringranibizumabtreatment
AT liangs dynamiccomplementproteinchangesinaqueoushumorandplasmaofpatientswithretinalveinocclusionduringranibizumabtreatment
AT wangj dynamiccomplementproteinchangesinaqueoushumorandplasmaofpatientswithretinalveinocclusionduringranibizumabtreatment
AT liuh dynamiccomplementproteinchangesinaqueoushumorandplasmaofpatientswithretinalveinocclusionduringranibizumabtreatment
AT zhouy dynamiccomplementproteinchangesinaqueoushumorandplasmaofpatientswithretinalveinocclusionduringranibizumabtreatment
AT xuh dynamiccomplementproteinchangesinaqueoushumorandplasmaofpatientswithretinalveinocclusionduringranibizumabtreatment
AT chenz dynamiccomplementproteinchangesinaqueoushumorandplasmaofpatientswithretinalveinocclusionduringranibizumabtreatment